The concept for the design of a salinomycin‐based cancer cell targeted DDS can be at least twofold: (1) salinomycin has a higher selective efficacy on stem‐like cancer cell populations compared with other cancer cells, for example, CD133+ pancreatic cancer cells or GBM cells, CD44high/CD24–/low or ALDH+ breast cancer cells, CD34+ neuroblastoma cells. The gene discussed is PROM1; the disease is neuroblastoma.